<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095771</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000393829</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0423</secondary_id>
    <secondary_id>JHOC-04041906</secondary_id>
    <nct_id>NCT00095771</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas</brief_title>
  <official_title>A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells and may be an effective treatment for patients with&#xD;
      glioma. Drugs such as arsenic trioxide may also make the tumor cells more sensitive to&#xD;
      radiation therapy. Combining arsenic trioxide with radiation therapy may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining arsenic trioxide with&#xD;
      radiation therapy in treating patients who have newly diagnosed gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of arsenic trioxide when administered with&#xD;
           radiotherapy in pediatric patients with newly diagnosed anaplastic astrocytoma,&#xD;
           glioblastoma multiforme, gliosarcoma, or intrinsic pontine glioma.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of arsenic trioxide (ATO).&#xD;
&#xD;
      Patients undergo radiotherapy once daily, 5 days a week, for approximately 6 weeks. Patients&#xD;
      concurrently receive ATO IV over 1 hour, 1-5 times weekly, for approximately 6 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ATO until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 3-36&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose as assessed by NCI CTCAE v. 3.0 following study completion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by NCI CTCAE v. 3.0 following study completion</measure>
  </primary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Clinical and neuroradiographic findings consistent with intrinsic pontine glioma&#xD;
&#xD;
               -  Histologically confirmed anaplastic astrocytoma, glioblastoma multiforme, or&#xD;
                  gliosarcoma&#xD;
&#xD;
                    -  Multifocal high-grade gliomas allowed&#xD;
&#xD;
          -  No exophytic tumors&#xD;
&#xD;
          -  No focal lesions&#xD;
&#xD;
          -  No underlying diagnosis of neurofibromatosis&#xD;
&#xD;
          -  No tumors originating in anatomic structures adjacent to the cerebellar peduncle or&#xD;
             cervical medullary junction&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100% OR&#xD;
&#xD;
          -  Lansky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No second-degree heart block&#xD;
&#xD;
          -  No absolute QTc interval &gt; 500 msec with normal potassium and magnesium levels&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
          -  Able to undergo MRI&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 28 days since prior biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or sargramostim&#xD;
             [GM-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior arsenic trioxide&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgery for the brain tumor allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior therapy for the brain tumor&#xD;
&#xD;
          -  More than 28 days since prior investigational drugs or devices&#xD;
&#xD;
          -  No concurrent amphotericin B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth J. Cohen, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>April 21, 2011</last_update_submitted>
  <last_update_submitted_qc>April 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2011</last_update_posted>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

